GS
LIMNW

GTS Securities’s Liminatus Pharma Warrants LIMNW Stock Holding History

GTS Securities’s Portfolio LIMNW Stock Details LIMNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$841 Sell
21,029
-8,671
-29% -$555 ﹤0.01% 1470
2025
Q4 		$1.04K Sell
29,700
-300
-1% -$30 ﹤0.01% 1345
2025
Q3 		$4.44K Buy
+30,000
New +$5.86K ﹤0.01% 1396

Other funds holding LIMNW

AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

GTS Securities's LIMNW Position: Q1 2026 in Review

GTS Securities reduced its Liminatus Pharma Warrants (LIMNW) stake by 29% in Q1 2026, selling an estimated $555 and leaving 21,029 shares worth $841. The position accounts for ﹤0.01% of the portfolio, ranked #1470.

GTS Securities first reported a position in LIMNW in Q3 2025 and has held it in 3 quarters since. The position peaked at $4.44K in Q3 2025. 21 funds tracked by Wall St. Rank hold LIMNW as of Q1 2026.

  • GTS Securities held 21,029 shares of Liminatus Pharma Warrants worth $841 as of Q1 2026.
  • GTS Securities sold 8,671 Liminatus Pharma Warrants shares in Q1 2026, an estimated $555.
  • Liminatus Pharma Warrants made up ﹤0.01% of GTS Securities's portfolio in Q1 2026, its #1470 holding.
  • GTS Securities first reported a position in Liminatus Pharma Warrants in Q3 2025 and has held it in 3 quarters since.
  • GTS Securities's Liminatus Pharma Warrants position peaked at $4.44K in Q3 2025.
  • 21 funds tracked by Wall St. Rank held Liminatus Pharma Warrants as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.